Qasim Rizvi, KSQ Therapeutics CEO
July 13, 2023 11:30 AM EDTUpdated 04:57 PM
Startups
Deals

Roche li­cens­es KSQ's PhI can­cer small mol­e­cule, with cash in­fu­sion to help bankroll biotech's TIL cell ther­a­pies

Kyle LaHucik

Senior Reporter

KSQ Ther­a­peu­tics quick­ly lined up an­oth­er Big Phar­ma part­ner­ship, this time al­ly­ing with Roche in on­col­o­gy, and it plans to use the cash wind­fall to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times